WELCOME
1B The Causeway, Goring By Sea, Worthing, BN12 6FA
Current time is 18:51 - Sorry, we're closed
Telephone: 01903 243351
Fax: 01903 705804 ( This will be permanently unavailable as of 1st April 2020)
Cancellation Line: 01903 705855 (Please leave a message)
ALERTS!
Medication Alerts
The following medication is currently having supply issues, please take this into consideration when ordering your next prescription.
| Medication | Strength | How is it affected? | Information from | Recommendation | Date |
|---|---|---|---|---|---|
| Lacosamide (Vimpat) | 50mg tablets | Out of stocl from early July until w/c 20 July | Department of Health | Vimpat 10mg/ml syrup remains available | 28/06/20 |
| Imipramine | 25mg tablets | Out of stock till early August 2020 | Department of Health | Imipramine 10mg tablets remain available.Unlicensed imports of imipramine 25mg tablets have been sourced | 28/06/20 |
| Mirtazapine | 15mg and 45mg orodispersible tablets | Out of stock till end of July 2020 | Department of Health | Unlicensed imports of mirtazapine orodispersible tablets have been sourced.Mirtazapine 15mg, 30mg and 45mg tablets remain available | 28/06/20 |
| Lodoxamide (Alomide) | 1% eye drops | Out of stock till w/c 24 August 2020 | Department of Health | Sodium cromoglycate eye drops and various antihistamine eye drops remain available | 28/06/20 |
| Acetazolamide SR | 250mg capsules | Out of stock until the end of July 2020
Acetazolamide immediate release 250mg tablets remain available. |
Department of Health | Clinicians to consider prescribing acetazolamide immediate release 250mg tablets | 14/04/20 |
| Ranitidine all Oral Formulation. | 75mg, 150mg and 300mg tablets
150mg and 300mg effervescent tablets 75mg/5ml oral solution |
An investigation by the Swiss and German regulatory agencies and the FDA, has identified a contaminant, Nnitrosodimethylamine (NDMA), a probable human carcinogen, in samples of ranitidine active substance. Several ranitidine products manufactured for the UK market may contain this active substance contaminated with NDMA. The MHRA has requested that all UK manufacturers using active ingredient from this source quarantine all stock whilst further investigations are ongoing. To date, one supplier, GSK, has undertaken a Class 2 recall of all their ranitidine products. MHRA is continuing to investigate the issue alongside the European Medicines Agency (EMA). Currently all but three UK manufacturers are affected by this situation, however this may change as the MHRA and EMA continue their investigations. There are insufficient supplies available from the unaffected manufacturers to continue to support current usage of oral ranitidine in the UK. Very limited supplies of unaffected oral ranitidine products may remain available and therefore the majority of patients will need to be switched to alternative products. This issue is affecting supplies globally. |
MHRA | Please consult your GP | 16/10/2019 |
| Zyban®
(bupropion hydrochloride) |
150mg prolonged release tablets | Out of stock from week commencing 15th June 2020 until the end of November 2020 | Department of Health | Unlicensed supplies of bupropion 150mg prolonged release tablets have been sourced. Champix® (varenicline tartrate) tablets, which are licensed for the treatment of nicotine dependence, are available. |
29/05/2020 |
If you have any questions about the above, please contact the surgery (after 11 am) or speak to a local pharmacy.
